Eclipse Regenesis

02/28/2022

raises awareness for the 7,000+ that affect over 25 million Americans! We're joining in celebrating the rare community. Learn how to : https://bit.ly/US-RDD22

05/19/2021

Short Bowel Syndrome (SBS) is a devastating condition where patients struggle to absorb life-sustaining nutrients from their diet. Patients with SBS are part of a rare community, as it’s estimated that only 10,000 to 20,000 people have the condition. Due to the lack of reporting, it is difficult to estimate the number of people with SBS.

05/15/2021

As part of Fogarty Innovation's Company Accelerator Program (CAP), we recently moved into a dedicated space within a 30,000 square foot state-of-the-art facility. The facility features office, laboratory, machine shop, conference, collaboration and recreation spaces.

04/06/2021

Big news! We have been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $256,000 to develop a minimally-invasive version of its Eclipse XL1 System™ for pediatric and adult patients with Short Bowel Syndrome. Today, there is no known restorative solution to SBS. This project will develop a technology that can be delivered endoscopically to the small intestine without the need of open surgery, thus offering a new, comprehensive treatment solution.

Eclipse Regenesis has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $256,000.

03/29/2021

Since we were recently accepted into Fogarty Innovation's Company Accelerator Program (CAP), we'd like to share a little more about what the program is all about!

The CAP is a six-month endeavor with the core focus to support early-stage companies in developing a comprehensive approach to address their desired opportunity. Fogarty's philosophy is to begin with “the end in mind.” Knowing the overall goal enables a thorough cross-functional assessment of actions needed to realize the company’s opportunity or identify barriers to success.

It's exciting and an honor to be part of the program and further our commitment to revolutionizing clinical outcomes for patients with Short Bowel Syndrome (SBS) and Intestinal Failure.

Learn more about the program here: https://bit.ly/fogartyi-cap

03/26/2021

We are honored to be part of Fogarty Innovation's new Company Accelerator Program (CAP), which supports early-stage companies in developing a comprehensive, cross-functional approach to address their desired opportunity by “starting with the end in mind.” The six-month program is designed to help companies clearly focus on their opportunity and identify barriers to success.

Imagine if your child’s body wasn’t able to absorb the nutrients it needs from food. That can be the result of short bowel syndrome (SBS), a malabsorption disorder caused by the lack of a functional small intestine. In pediatrics, common causes of SBS are necrotizing enterocolitis, volvulus and...

03/23/2021

With a lifelong commitment to the treatment of Short Bowel Syndrome (SBS) and Intestinal Failure, our founders and our team of clinical experts drive innovation with a passion for change. Our team offers a complimentary approach to innovation by proudly representing the leading pediatric healthcare organizations and intestinal rehabilitation clinics across the United States. Eclipse Regenesis is committed to revolutionizing clinical outcomes for patients with SBS and intestinal failure.